BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 26210287)

  • 21. Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy--a single institution experience.
    Zang J; Li C; Luo SQ; Wang JH; Xu M; Zhao LN; Li WW; Yang H; Xiao F; Hitchcock YJ; Shi M
    Ann Hematol; 2015 Apr; 94(4):583-91. PubMed ID: 25409913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma.
    Kim HS; Kim KH; Kim KH; Chang MH; Ji SH; Lim DH; Kim K; Kim SJ; Ko Y; Ki CS; Jo SJ; Lee JW; Kim WS
    Leuk Lymphoma; 2009 May; 50(5):757-63. PubMed ID: 19330658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating Epstein-Barr virus-encoded micro-RNAs as potential biomarkers for nasal natural killer/T-cell lymphoma.
    Komabayashi Y; Kishibe K; Nagato T; Ueda S; Takahara M; Harabuchi Y
    Hematol Oncol; 2017 Dec; 35(4):655-663. PubMed ID: 27709652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.
    Leung SF; Chan KC; Ma BB; Hui EP; Mo F; Chow KC; Leung L; Chu KW; Zee B; Lo YM; Chan AT
    Ann Oncol; 2014 Jun; 25(6):1204-8. PubMed ID: 24638904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
    Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
    Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase.
    Yang J; Li P; Piao Y; Liu X; Wei L; Sang W; Zhang L; Wang L
    Front Immunol; 2022; 13():829366. PubMed ID: 35371002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
    Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
    Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.
    Lin JC; Wang WY; Chen KY; Wei YH; Liang WM; Jan JS; Jiang RS
    N Engl J Med; 2004 Jun; 350(24):2461-70. PubMed ID: 15190138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pretreatment whole blood Epstein-Barr virus DNA predicts prognosis in Hodgkin lymphoma.
    Qin JQ; Yin H; Wu JZ; Chen RZ; Xia Y; Wang L; Zhu HY; Fan L; Li JY; Liang JH; Xu W
    Leuk Res; 2021 Aug; 107():106607. PubMed ID: 33957372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical characteristics and prognostic analysis of advanced-stage extranodal NK/T cell lymphoma].
    Wei C; Zhang Y; Wang W; Zhang L; Zhang W; Zhou DB
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):462-468. PubMed ID: 32654458
    [No Abstract]   [Full Text] [Related]  

  • 31. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma.
    Lei KI; Chan LY; Chan WY; Johnson PJ; Lo YM
    Clin Cancer Res; 2002 Jan; 8(1):29-34. PubMed ID: 11801537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival.
    Visco C; Falisi E; Young KH; Pascarella M; Perbellini O; Carli G; Novella E; Rossi D; Giaretta I; Cavallini C; Scupoli MT; De Rossi A; D'Amore ES; Rassu M; Gaidano G; Pizzolo G; Ambrosetti A; Rodeghiero F
    Oncotarget; 2015 Jul; 6(21):18653-63. PubMed ID: 26087198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation.
    Xuan L; Jiang X; Sun J; Zhang Y; Huang F; Fan Z; Guo X; Dai M; Liu C; Yu G; Zhang X; Wu M; Huang X; Liu Q
    Transplantation; 2013 Sep; 96(6):560-6. PubMed ID: 23842192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma.
    Haverkos BM; Gru AA; Geyer SM; Bingman AK; Hemminger JA; Mishra A; Wong HK; Pancholi P; Freud AG; Caligiuri MA; Baiocchi RA; Porcu P
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl(Suppl):S181-S190.e4. PubMed ID: 27521316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
    Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
    Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients.
    Spacek M; Hubacek P; Markova J; Zajac M; Vernerova Z; Kamaradova K; Stuchly J; Kozak T
    APMIS; 2011 Jan; 119(1):10-6. PubMed ID: 21143522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients.
    Kim SJ; Park S; Kang ES; Choi JY; Lim DH; Ko YH; Kim WS
    Ann Hematol; 2015 Jan; 94(1):71-8. PubMed ID: 25082384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome.
    Li PF; Mao YZ; Bai B; Gao Y; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
    Ann Hematol; 2018 Dec; 97(12):2381-2389. PubMed ID: 30116872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic changes in plasma Epstein-Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study.
    He SS; Wang Y; Bao Y; Cai XY; Yang XL; Chen DM; Chen Y; Lu LX
    Cancer Med; 2018 Apr; 7(4):1110-1117. PubMed ID: 29493874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases.
    Su YJ; Wang PN; Chang H; Shih LY; Lin TL; Kuo MC; Chuang WY; Wu JH; Tang TC; Hung YS; Dunn P; Kao HW
    Eur J Haematol; 2018 Sep; 101(3):379-388. PubMed ID: 29908084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.